Mechanisms of long-term cognitive dysfunction of sepsis: from blood-borne leukocytes to glial cells

Monique Michels¹, Amanda V. Steckert², João Quevedo²,³, Tatiana Barichello²,³ and Felipe Dal-Pizzol¹*

Abstract

Several mechanisms are associated with brain dysfunction during sepsis; one of the most important are activation of microglia and astrocytes. Activation of glial cells induces changes in permeability of the blood-brain barrier, secretion of inflammatory cytokines, and these alterations could induce neuronal dysfunction. Furthermore, blood-borne leukocytes can also reach the brain and participate in inflammatory response. Mechanisms involved in sepsis-associated brain dysfunction were revised here, focusing in neuroinflammation and involvement of blood-borne leukocytes and glial cells in this process.

Keywords: Sepsis, Glial cells, Blood-borne leukocytes, Neuroinflammation, Long-term cognitive dysfunction

Review

Introduction

Sepsis is referred as a systemic inflammatory response due to an infection [1] and presents a wide spectrum of severity: from severe sepsis to septic shock and multi-organ dysfunction syndrome [2]. It is a major cause of death in intensive care unit (ICU) and its incidence is increasing worldwide [3–5]. Sepsis-associated encephalopathy (SAE) is associated with an increased rate of morbidity and mortality. It is not fully understood the exact mechanism that drives brain dysfunction during sepsis development, but brain inflammation and oxidative stress are possible players [6].

Dysfunction of both innate and adaptive immune response plays a role in the induction of abnormal levels of immunoregulatory molecules that result in sepsis [7]. However, participation of effector immune system cells could also impair host response to the infective agents and induces tissue damage [8]. Thus, both an overwhelming inflammatory response and secondary tissue damage and cell dysfunction [9], and a decrease in the immune responses and inadequate infection control [8], could be associated with sepsis pathogenesis [9].

The clinical manifestations of sepsis are variable, depending on the initial site of infection, pathogenic organism, underlying health status of the patient, and time of treatment [10]. The majority of patients with sepsis develop reversible brain dysfunction,
called sepsis-associated delirium or septic encephalopathy (SAE) [11, 12]. Moreover, septic patients are at risk for long-term cognitive impairment [12] that could be associated with cerebral atrophy [13–15]. Diagnosing brain dysfunction during sepsis implies a systematic approach of all potential factors. Furthermore, several mechanisms have been proposed to explain the pathophysiology of SAE [6, 7, 16–18]. SAE development involves cellular damage, mitochondrial and endothelial dysfunction, neurotransmission, and calcium homeostasis disturbances. Cerebral blood flow, integrity of blood-brain barrier (BBB) and cerebral water content may also be affected [6, 13, 19]. Apart from brain specific aspects, development of SAE could involve hypoxemia, hypotension, and electrolytes disturbances [20, 21]. Additionally, the long-term effects of sepsis in humans have been evaluated in some studies, all of which underscore the connection between SAE and subsequent cognitive decline [14, 15]. Mechanisms that link SAE and long-term cognitive dysfunction are not well understood, thus evidences that link neuroinflammation and both acute and long-term sepsis-associated brain dysfunction were here reviewed.

**Neuroinflammation**

In central nervous system (CNS) immune response to injury is initiated mainly by microglia and astroglia. Neuroinflammation is characterized by activation of microglial cells, followed by changes in permeability of BBB and infiltration of peripheral immune cells into CNS parenchyma. These alterations lead to secretion of inflammatory cytokines and neuronal dysfunction [22], and seem to be a common feature to all neuroinflammatory syndromes [23].

Besides acute symptoms, CNS dysfunction secondary to sepsis is characterized by long-term cognitive impairment. In this context, it has been demonstrated that cytokine levels, oxidative stress, and energetic metabolism alterations seen early after sepsis may persist for up to 30 days and this could be associated with cognitive damage [24–26]. Actually, several groups using different models of sepsis could reproduce cognitive impairment (from inhibitory avoidance to object recognition) that is similar to what is observed in humans [14, 27]. Thus, systemic inflammation is emerging as a significant driver of cognitive decline in the aged and vulnerable brain. A growing body of clinical and preclinical evidence demonstrates that various peripheral inflammatory insults can exacerbate CNS inflammation. In addition, sepsis itself is an independent risk factor for dementia [28]. In this context, severe systemic inflammation can produce a new neuropathology or accelerate cognitive decline previously installed [29]. Furthermore, both human and experimental studies suggest that cognitive impairment and dementia are important risk factors for delirium [30].

Among the far-reaching and sustained systemic effects of sepsis are hemodynamic alterations, which cause the changes in cerebral blood flow that are implicated in SAE. Although reduced cerebral blood flow and oxygenation occur in sepsis, they do not appear to drop low enough to threaten neuronal viability or cause electroencephalogram changes at least in preclinical models of SAE [31]. However, even when cerebral blood flow is sufficient to ensure neuronal integrity, slight reductions could still contribute to SAE when higher energy demands are present, as in the case of cognitive processing [31]. In addition, there are some evidences of alterations in the control of brain perfusion both in animal models and humans [32–35]. These alterations in auto regulation of brain perfusion could be associated with inflammation and the pathogenesis of SAE.
Abundant data have suggested adaptive immunity as a key regulator of brain cell renewal, behavior, learning, and memory. Immune deficiency was linked to impaired brain plasticity, and when adaptive immunity was boosted, brain function was restored or even enhanced [36–40]. Thus, neuroinflammation could be associated with brain (dys)function, inhibition of hippocampal neurogenesis, and disruption of cognitive ability [41]. Although this is clearly demonstrated in neurodegenerative disorders, its role in sepsis associated long-term cognitive impairment is less clear.

**Microglia—do different phenotypes have different impact in brain dysfunction?**

Microglia activation has a major role in the generation of oxidative damage and inflammation in the brain during several different CNS diseases. As demonstrated to peripheral immune cells, microglia are able to express several pathogens/damage recognition receptors, such as the toll-like receptors (TLRs). TLR4 and TLR2 expressed in microglial cells have been specifically associated with both neuroinflammation and clearance of aggregated proteins [42, 43]. Thus, it is plausible to suppose that microglia activation is a major determinant of SAE and long-term cognitive impairment after sepsis [44].

Morphology and density of microglia is region specific, being more common in the grey area of the CNS [45]. These differences may be associated with functional heterogeneity, but little is known about the nature of this heterogeneity among and within brain regions. Microglia share common features of cells of the myeloid lineage; they have the ability to secrete a plurality of immunomodulatory molecules, which coordinate signals to neighbor and circulating cells [46]. Thus, during inflammation, activated microglia modify the responses of supporting cells through the release of a diversity of factors [47].

Microglia show morphological and functional diversity in the brain, ranging from the ramified, “resting” phenotype associated with tissue surveillance in the healthy brain to amoeboid, cytokine-secreting, and phagocytic phenotypes in disease states [48]. Microglial activation, which plays a central role in neuroinflammation may be regulated by several intercellular interactions involving cell-surface molecules and soluble mediators, such as cytokines, reactive oxygen species (ROS), and neurotransmitters [22]. In healthy brain, microglial cells display a “homeostatic” phenotype, which monitor the surrounding environment [49]. In this phenotype, microglia express surface molecules and secrete soluble factors, which influence astrocytes and neuron function [50], promote the clearance of cellular debris and aggregated proteins [51]. Accordingly, microglia exhibit at least four functional behaviors: surveillance, neuroprotection, phagocytosis, and toxicity [23]. In addition, microglia could be “primed”, and in this context produces exaggerated levels of inflammatory cytokines in response to a stimulus [52]. Thus, it seems that microglia can be a double-edged sword [53].

Recent studies have demonstrated that microglia may simultaneously exhibit M1 and M2 phenotypes [54]. M1 cells can be neurotoxic, probably through the production of cytokines such as IL-6, IL-12, and TNF-α, reactive oxygen species, and deregulated release of glutamate [55]. Activated brain microglia can be neuroprotective by assuming an M2-like phenotype [56–58], a phenomena similar to what occur in macrophages. In response to lipopolysaccharide (LPS), TNF-α and/or IFN-γ, macrophages become classically activated and acquire an M1 phenotype, which express several pro-inflammatory cytokines and enzymes that promote a sustained tissue inflammation. In contrast, alternative activation in response to IL-4, IL-13, glucocorticoids, TGF-β, and/or IL-10, macrophages differentiate into the anti-inflammatory M2 phenotype, which is associated
with the resolution of inflammation and tissue repair [59–61]. It seems that modulation of the M2 phenotype could represent a beneficial aspect of brain immune response during inflammatory injury [62–64], but to date, there is no sufficient information regarding M2 phenotype during the development of SAE.

Free radicals are a major causal factor of secondary insults, such as axonal damage or membrane lipid peroxidation, which result in evolving neurological deficits [65, 66]. Reactive nitrogen and oxygen species, as well as cytokines produced by M1-like microglia, such as TNF-α, can directly induce neuronal death [67–70]. Among the most frequently cited proinflammatory and damaging aspects of microglial activation is the production of nitric oxide (NO) via nitric oxide synthase (iNOS) [32]. iNOS expression in response to sepsis has been detected in neuronal and glial cells [71, 72]. In this context, neurons are highly sensitive to the toxic effects of NO [73]. NO produced by activated microglia is able to induce neuronal apoptosis [74] even when activated glial cells are present at relatively low numbers [75, 76]. In a model of systemic endotoxemia, it was observed an early upregulation of iNOS in several different brain regions, predominantly in microglial cells, and is associated with both neuronal and glial cell apoptosis [77]. Furthermore, iNOS activation can be found even late times after sepsis resolution [78]. NO might also include the stimulation of excitotoxicity, because the application of an acute low dose of the NMDA receptor antagonist MK-801 prevents memory deficits in the cecal ligation and puncture rat model [79].

In addition, microglia are able to generate oxidative burst involving the induction of multiple enzymes/complexes including NADPH oxidase and myeloperoxidase (MPO) [71]. Thus, a sort of strong oxidant agents can be produced by activated microglia, including superoxide, nitric oxide, hypochlorous acid, peroxynitrite, and hydroxyl radical that contributes to the progression of brain damage during SAE [80]. On the other hand, microglial can also help in clearance of free radicals (for example, by regulating ceruloplasmin levels), thus preventing free radical-mediated neuronal damage [70].

Activated microglia can also release large amounts of glutamate that can induce neuronal dysfunction [81]. High extracellular glutamate concentrations in the CNS promote excitotoxicity, which has been involved in various pathological conditions, including acute CNS trauma such as brain or axonal injury [82], ischemia [83], and epilepsy [84], as well as in chronic neurodegenerative disorders such as Parkinson’s disease (PD), AD and amyotrophic lateral sclerosis (ALS) [85]. When CNS is injured, glutamate buffering cells, astrocytes, are lost and the damaged site is repopulated by M1-like activated microglia [86]. Although neurons, astrocytes, and homeostatic microglia can release moderate levels of glutamate, M1-like activated microglia can release toxic amounts of glutamate through a mechanism that involves connexin channels and the cystine/glutamate antiporter system [81, 87]. Excessive stimulation of the ionotropic glutamate receptor N-methyl-D-aspartate (NMDA) in neurons promotes the deregulation of calcium influx, which leads to cellular death [88]. Thus, M1 phenotype exacerbates neuronal dysfunction by several different pathways, which include, at least, cytokine and ROS production and glutamate excitotoxicity [81, 88].

Furthermore, the concept of primed microglia is relevant to the understanding of its role in brain dysfunction during sepsis development. A primed microglia is able to make an exaggerated response to a typical stimulus [80]. Using the ME7 model of prion disease, Cunningham and colleagues demonstrated that the primed brain
showed exaggerated response to several challenges, including LPS, poly I:C, IL-1β, and TNF-α [89–91]. This exaggerated response is phenotypically seen both in acute and chronic brain dysfunction after a systemic LPS challenge. This paradigm mimics what happens in the clinical setting. Both acute and chronic brain dysfunction is more severe/frequent in the aged or in patients with mild cognitive impairment or clinical dementia; the clinical equivalent of the primed brain [92]. Little is known about the mechanisms of microglia activation during sepsis development. Our group recently demonstrated in an animal model of sepsis that the activation of microglia is crucial to acute brain inflammation and oxidative damage [44]. In this setting, microglia activation seems to be depend in part to the activation of CD40–CD40 ligand pathway. The activation of CD40 pathway drives microglia activation, brain inflammation, and oxidative damage and blood-brain barrier dysfunction. Using in vivo two-photon imaging in mice, Gyoneva et al., 2014 [93] showed that systemic inflammation affects the baseline morphology and dynamics of microglia 48 h after the initial stimuli. After systemic inflammation, microglia moved their processes at significantly higher mean speeds, which led to longer distances traveled, and this effect seems to be mediated by adenosine receptors.

Microglia activation is not only relevant to the acute phase of brain dysfunction after sepsis. In a model of endotoxemia, it was observed a long-lasting activation of microglia, but not astrocytes, and this was associated with decrease in expression of plasticity related genes and brain neurogenesis [94]. A single injection of LPS is able to induce microglia activation and inflammatory gene transcription, but not neuronal damage, as long as 2 months after the initial stimuli [78]. This was associated with disrupted synaptic structure and long-lasting behavioral deficits.

Is there a role for astrocytes in brain dysfunction after sepsis?

During CNS injury, astrocytes become reactive, migrate to the damaged site and form glial scar (reactive astrogliosis) [95]. In pathological conditions, a role for reactive astrogliosis as supportive or detrimental to neuronal survival remains undefined [96, 97]. Studies have shown that astrogliosis can have neuroprotective role by preserving bioenergetics [98] and trophic support [99]. In addition, astrocytes can prevent excitotoxicity [100, 101], decrease oxidative stress [102, 103], and apoptosis in neurons [104]. Astrocyte membranes contain numerous neurotransmitter receptors and transporters and can therefore sense and regulate formation, stability, and efficacy of synapses [105], and this was clearly demonstrated in dopaminergic neurons in vitro [106]. Studies suggest that by transforming from a basal to a reactive state, astrocytes neglect their supportive functions, thus rendering neurons vulnerable to neurotoxins, including proinflammatory cytokines and ROS [104].

Astrocytes seem to be also important to the maintenance of the BBB function [107–109]. They are suggested to regulate BBB permeability, water and ion exchange [110–112]. Presence of numerous astrocyte end-feet close to the BBB allows for a rapid regulation of BBB permeability [113]. Several recent studies have suggested a role for vascular factors in SAE-related injury of the brain vascular endothelium, changes in BBB permeability and microcirculatory dysfunction [114–116]. In this context, they can protect against neuroinflammation by invading T cells contributing to the immune privilege of the CNS [117]. Chapouly et al., 2015 [118] showed reactive astrocytes drive blood-brain barrier opening, via production of vascular endothelial growth factor A (VEGFA). In addition, thymidine phosphorylase
(TYMP; previously known as endothelial cell growth factor 1, ECGF1) was identified as a second key astrocyte-derived permeability factor, which interacts with VEGFA to induce blood-brain barrier disruption [119]. Both are co-induced by NFκB1 in human astrocytes as a response to interleukin 1 beta (IL-1β), and inactivation of VEGFA in vivo potentiates TYMP induction. Nowadays, the BBB is understood as a complex regulated system. Terms such as neuro- or gliavascular unit (NVU, GVU) describe the strong influence of the microenvironment on the brain endothelium [120]. Neighboring cell types such as astrocytes, pericytes, microglia, or even neurons are known to influence the functionality of BBB in health as well as in disease, which is supported by their physical proximity and consequent small diffusion distances for signaling molecules [120, 121]. Astrocytes can also downregulate microglial activation by secretion of anti-inflammatory substances such as transforming growth factor (TGF) and prostaglandin E2 (PGE2) [122, 123], resembling a M2 phenotype, and may thereby limiting neuroinflammation.

Dysregulation of astroglial glutamate transporters has been implicated in neuroinflammation. Astrocytes are capable of modulating NMDAR activity through glutamate uptake transporters [121]. Dumont et al., 2014 [124] demonstrated the influence of inflammation on the control of glutamate transmission by astrocytes. Excitotoxic neuronal damage resulting from excessive glutamate is frequently associated with impaired handling of extracellular glutamate by astrocytes. Sepsis is associated with impaired glutamatergic transmission in brain, and inhibition of glutamate uptake by astrocytes through mechanisms that can be modulated by intracellular ascorbate [125]. Astrocytes take up DHAA (dehydroascorbic acid) and use it to synthesize ascorbate that is exported in response to increased glutamate concentrations [126].

Hernandes and colleagues (2014) [127] demonstrated that microglia and astrocytes were activated as many as 5 days after sepsis onset in the hippocampus and that this activation was dependent on the presence of functional Nox2. The results presented by Hernandes et al., 2014 [127] provide evidence that Nox2 is the main source of ROS involved in the oxidative damage to the hippocampus in SAE and that Nox2-derived ROS are determining factors for cognitive impairments after sepsis. They show the importance of Nox2-derived ROS as a central mechanism in glial cells activation and identify Nox2 as a potential target for future therapies to prevent SAE. Nox2 has been shown to regulate intracellular ROS levels in microglia and to result in both amplification of proinflammatory cytokines production and priming of microglia to additional stimuli [127]. Nox2 is essential for glial cell activation and emphasize the critical role of oxidative damage and Nox2-derived ROS as central factors contributing to acute and long-term brain dysfunction after sepsis [128].

In vitro experiments have recently shown that the stimulation of astrocytes with ligands for TLRs 2, 4, 5, or 6 enhances the production of ROS, IL-1β, IL-6, glutamate, and TNF-α, thereby favoring neuronal loss [129, 130]. Thus, activated astrocytes could display a neurotoxic behavior similar to that of activated microglia during inflammation of CNS [22]. An important and differential feature of activated astrocytes is the production of chemokines, including CCL2, CCL5, CCL20, CXCL10, CXCL12, CXCL1, CXCL2, and CX3CL1 [131]. These chemokines are involved in the recruitment of microglia, monocytes/macrophages, T cells and dendritic cells (DCs) into the inflamed sites of the CNS, thus favoring the formation
of a more complex and long-lasting immune response during neuroinflammation [22]. Recently it was demonstrated that, as for microglia, astrocytes could also be primed [91]. Differently from microglia, primed astrocytes synthetize chemokines (CXCL1 and CCL2), resulting in markedly neutrophil, T cell and monocyte infiltration in the diseased brain. This suggests that primed astrocytes and microglia have different roles in brain inflammation during sepsis. These results point to a mixed constellation of inflammatory cells inducing brain damage during sepsis. There is an early role to activated/primed microglia that could be sustained for long periods of time after sepsis resolution. In addition, there is a second player that depends on the chemo attractive effects of activated astrocytes, and probably also depends on the breakdown of the BBB that are brain infiltration by peripheral inflammatory cells.

**Blood-borne leukocytes and brain dysfunction**

Monocyte-macrophage cells have the ability to phagocytize bacteria and interact with their products, resulting in the release of proinflammatory mediators, such as glutamate, free radicals, proteases, cytokines, leukotrienes, and nitric oxide [132–134] that could contribute to brain dysfunction [135, 136]. This can be further aggravated by the dysfunction of the BBB that is implicated in the pathogenesis of SAE [137]. Systemic-derived and brain-derived inflammatory mediators drive changes in the blood-brain barrier and help the influx of inflammatory cells and toxic mediators into the brain. We had previously demonstrated that activation of the brain microvasculature is an early event in an animal model of sepsis. There was an increase in leukocyte rolling and adhesion, as well as, cell migration into the brain that could contribute to brain inflammation after sepsis [138]. Activation of brain endothelial cells seems to be the main target of circulating inflammatory mediators to activate the brain circuits during systemic inflammation [139]. Recently, it was shown that after sepsis there was an increase in brain endothelial levels of CXCL1 and CX3CL1. This was dependent on leukocyte adhesion and purinergic signaling [140]. This signaling triggered microglia traffic to the injured site and could partially explain how systemic and brain inflammation communicates. In addition, endothelial cell activation seems to depend on estrogen signaling. Systemic LPS, TNF, or IFN administration affects endothelial cell function and BBB integrity only in males and reproductively senescent females but was not apparent in young females [141].

In addition, several immune components can actively cross the BBB via specific carrier inflammation during systemic inflammation [142]. Evidence from sepsis models suggests a role for C5a, and cytokines in the pathogenesis of the breakdown of the blood-brain barrier and the subsequent edema [143–146]. Thus, it seems that BBB dysfunction is a major fueling brain inflammation after sepsis. The mechanisms that drive BBB dysfunction are not fully understood, but include at least the activation of MMP-2, MM9, and MMP8 [147, 148]. These proteases are responsible to degrade key proteins that maintain the functionality of the BBB.

In addition to the innate immunity, lymphocytes could also be implicated in brain inflammation after systemic inflammation. In a neonate model of systemic inflammation, an important step of brain inflammation is the influx of the peripheral leukocytes through the choroid plexus. In this model, brain influx of leukocytes is dependent of an early onset
of TH17-mediated immunity [149]. Actually, the choroid plexus has been considered as a possible route for cells to transfer to the central nervous system. Systemic inflammation stimulates expression of TLR and increases CSF cytokines and leukocytes levels, probably by affect blood-cerebrospinal fluid barrier (BCSFB) regulation [150]. This could be a double-edge sword, since deregulation of BCSFB was associated with worse signs of systemic inflammatory response syndrome in an animal model [148]. After systemic inflammation, the choroid plexus upregulated genes cluster into families implicated in immune-mediated cascades, in extracellular matrix remodeling, and in facilitating entry of cells into the cerebrospinal fluid, whereas those downregulated participate in maintenance of the barrier function [151, 152]. These findings reinforce the role for BCSFB in recruit blood-borne inflammatory cells, and in the amplification of brain.

Conclusions
Glial cells are important for the development of brain inflammation (Fig. 1). It seems reasonable to suppose that they play a central role in brain dysfunction during sepsis development. Furthermore, dysfunction of BBB and migration of blood-borne leukocytes take place in brain inflammation as well (Fig. 1). A more in depth understanding of the role of different subtypes of inflammatory cells and the specific role of each one is needed to further increase our understanding on the mechanisms of sepsis-associated brain dysfunction.

![Fig. 1](image_url) The transition from healthy to sepsis-associated brain dysfunction. In healthy conditions, resting microglia and astrocytes are predominant and are important to maintain several different brain functions. In addition, microglia could be primed, and in this context produces exaggerated levels of inflammatory cytokines in response to a stimulus. Systemic inflammation could activate both resting and primed microglia. Activated microglia could simultaneously exhibit M1 and M2 phenotypes. Despite the fact that classically M1 phenotype is associated with brain damage, during some conditions, the M2 phenotype could also be detrimental to brain function. In addition, astrocytes are also activated, lose the ability to maintain low the extracellular levels of glutamate, to maintain the integrity of the blood-brain barrier, and secrete chemokines. All these modifications are powerful stimuli to the chemotaxis of blood-borne leukocytes that also contribute to sepsis-associated brain dysfunction.
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MM and AVS drafted the manuscript, TB, JQ, and FDP have been involved in drafting the manuscript and revising it critically for important content. All authors read and approved the final version of the manuscript.

Acknowledgements
This study was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Programa de Apoio aos Núcleos de Excelência (PRONEX-Project NENASC), Fundação de Apoio à Pesquisa do Estado de Santa Catarina (FAPESC) all from Brazil. MM and AVS received scholarships from CAPES and CNPq; TB, JQ, and FDP are supported by research fellowships from CNPq.

Author details
1Laboratory of Experimental Pathophysiology, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil. 2Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC, Brazil. 3Center for Translational Psychiatry, Department of Psychiatry and Behavioral Sciences, Medical School, The University of Texas at Houston, Houston, TX, USA.

Received: 28 July 2015 Accepted: 21 October 2015
Published online: 29 October 2015

References
1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Silbavid WJ (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655
2. Vincent JL, Taccone F, Schmit X (2007) Classification, incidence, and outcomes of sepsis and multiple organ failure. Contrib Nephrol 156:64–74
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7):1303–1310
4. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of septic patients in the United States from 1979 through 2000. New Eng J Med 348(16):1546–1554
5. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL (2007) Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 35(2):1244–1250
6. Bozza FA, D’Avila JC, Ritter C, Sonneville R, Sharshar T, Dal-Pizzol F (2013) Bioenergetics, mitochondrial dysfunction, and oxidative stress in the pathophysiology of septic encephalopathy. Shock 39(1):10–16
7. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420(6917):885–891
8. Mauri C, Bosma A (2012) Immune regulatory function of B cells. Annual Rev Immunol 30:221–241
9. Dore K, Dhainiiddy K (2012) Immunosuppression. Curr Opin Organ Transplant 17(6):616–618
10. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS (2003) 2001 International Sepsis Definitions Conference. Crit Care Med 31:1250–1256
11. Hopkins RO, Jackson JC (2006) Long-term neurocognitive function after critical illness. Chest 130:869–878
12. Dellinger RP, Levy MM, Rhodes A, Annane D, Gafarch H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaaechke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb RJ, Beale RI, Vicent JL, Moreno R (2013) Surviving Sepsis Campaign Guidelines Committee Including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock 2012. Crit Care Med 41:580–637
13. Pytel P, Alexander JJ (2009) Pathogenesis of septic encephalopathy. Curr Opin Neurol 22:283–287
14. Iwashyna TJ, Ely EW, Smith DM, Langa KM (2010) Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 304(17):1794
15. Sennrnler A, Widmann CN, Okula T, Utzsch H, Kaiser M, Widman G, Mommorn F, Weide J, Fliessbach K, Hooft A, Jassen F, Putensen C, Henkel MA (2013) Persistent immunoapathic, hippocampal atrophy and EEG changes in sepsis survivors. J Neurol Neurosurg Psychiatry 846:62–69
16. Gunther ML, Morandi A, Ely EW (2008) Pathophysiology of delirium in the intensive care unit. Crit Care Clin 24(5):65–65
17. Comim CM, Constantino LC, Barichello T, Streck EL, Quevedo J, Dal-Pizzol F (2009) Cognitive impairment in the septic brain. Curr Neurovasc Res 6(3):194–203
18. Flierl MA, Rittirsch D, Huber-Lang MS, Stahl PF (2010) Pathophysiology of septic encephalopathy—an unsolved puzzle. Crit Care 14:165
19. Steckert AV, de Castro AA, Quevedo J, Dal-Pizzol F (2014) Sepsis in the central nervous system and antioxidant strategies with N-acetylcysteine, vitamins and statins. Curr Neurovasc Res 11(1):83–90
20. Kamel H, Iadecola C (2012) Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol 69:376–381
21. Quan N, Banks WA (2007) Brain-immune communication pathways. Brain Behav Immun 21:727–735
22. González H, Elgueta D, Montoya A, Pacheco R (2014) Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol 274:1–13
23. Chen Z, Trapp B (2015) Microglia and neuroprotection. J Neurochem doi:10.1111/jnc.13062
24. Comim CM, Casol Jr OJ, Constantino LS, Felisberto F, Petroniho F, Rezin GT, Scaini G, Daufenbach JF, Streck EL, Quevedo J, Dal-Pizzol F (2011) Alterations in inflammatory mediators, oxidative stress parameters and energetic metabolism in the brain of sepsis survivors rats. Neurochem Res 36(2):304–311
59. Shechter R, Miller G, Yovel G, Rosenzweig N, London A, Ruckh J, Kim KW, Klein E, Kalchenko V, Bendel P, Lira SA, Jung S, Schwartz M (2013) Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 38:555–569

60. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122:787–795

61. Sandiego CM, Gallezot J, Pittman B, Nabulusi N, Lim K, Lin S, Matsukey D, Lee J, O’Connor KC, Huang Y, Carson RE, Hannestad J, Cosgrove KP (2015) Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. PNAS 112:12468–12473

62. Mecha M, Felu A, Carrillo-Salinas FJ, Rueda-Zubiaurre A, Ortega-Gutiérrez S, de Solà RG, Guaza C (2015) Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav Immun 49:233–245

63. Pan J, Jin JL, Ge HM, Yin KL, Chen X, Han LJ, Chen Y, Qian L, Li XX, Yu X (2015) Mallbato A regulates microglia M1/M2 polarization in experimental stroke in a PPAR-δ-dependent manner. J Neuroinflammation 12(12):51

64. Won S, Lee JK, Stein DG (2015) Recombinant tissue plasminogen activator promotes, and progesterone attenuates, microglia/macrophage M1 polarization and recruitment of microglia after MCAO stroke in rats. Brain Behav Immun 50:889–51591(15):00160–00169

65. Siesjo BK, Agardh CD, Bengtsson F (1989) Free radicals and brain damage. Cerebrovasc Brain Metab Rev 1:165–211

66. Wagner KR, Sharp FR, Ardzzone TD, Lu A, Clark JF (2003) Heme and iron metabolism: role in cerebral hemorrhage. J Cereb Blood Flow Metab 23:620–652

67. Ferrari CC, Pott Godoy MC, Tarelli F, Chentoff D, Megeno AM, Ponteski FJ (2006) Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiology Dis 24:183–193

68. Gordon R, Anantharam V, Kanthasamy AG, Kanthasamy A (2012) Proteolytic activation of proapoptotic kinase protein cdc6a by tumor necrosis factor alpha death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation 9:82

69. Reale M, Iarlì T, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofri M (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Beh Immunity 23:55–63

70. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S (2002) Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci 22:6578–6586

71. Jacobs RA, Satta MA, Dahia PL, Chow SL, Grossman AB (1997) Induction of nitric oxide synthase and interleukin-1beta, but not heme oxygenase, messenger ma in rat brain following peripheral administration of endotoxin. Brain Res Mol Brain Res 49(1–2):238–246

72. Wong ML, Rettoni V, al-Sheikhlee A, Bongiorno PB, Canteros G, McCann SM, Gold PW, Licinio J (1996) Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nat Med 2(5):581–584

73. Heneka MT, Loschmann PA, Gleichmann M, Weller M, Schulz JB, Wullner U, Klockgether T (1998) Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. J Neurochem 71(1):88–94

74. Peterson PK, Hu S, Anderson WR, Chao CC (1994) Nitric oxide production and neurotoxicity mediated by activated microglia from human versus mouse brain. J Infect Dis 170(2):457–460

75. Chao CC, Hu S, Moltitz TW, Shaskan EG, Peterson PK (1992) Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 149(8):2736–2741

76. Bal-Price A, Brown GC (2001) Inflammatory neurodegeneration mediated by nitric oxide from activated glia inhibits neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 21(7):6480–6491

77. Semmler A, Okulla T, Sastre M, Dumitrescu-Ozimek L, Heneka MT (2005) Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J Chem Neuroanat 30:144–157

78. Verheyers M, Hermens H, Hermann S, Kummer MP, Tenfel D, Semmler A, Berger M, Schafers M, Heneka MT (2009) NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits. J Neurosci 29(45):14177–14184

79. Cassol-RJ, Oji, Comin CM, Constantino LS, Rosa DV, Mango LA, Steertz L, Kapczinski F, Romano-Silva MA, Quevedo J, Dal-Pizzolo F (2011) Acute low dose of MK-801 prevents memory deficits without altering hippocampal DARPP-32 expression and BDNF levels in sepsis survivor rats. J Neuroimmunol 230(1–2):48–51

80. Cunningham C (2013) Microglia and neurodegeneration: the role of systemic inflammation. GLIA 61:71–90

81. Takeuchi H, Jin S, Wang J, Zhang G, Kawasakuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A (2006) Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 281:21362–21368

82. Alessandri B, Bullock R (1998) Glutamate and its receptors in the pathophysiology of brain and spinal cord injuries. Prog Brain Res 116:303–330

83. Lipton P (1999) Ischemic cell death in brain neurons. Physiol Rev 79:1431–1568

84. Fountain NB (2000) Status epilepticus: risk factors and complications. Epilepsia 41(2):S23

85. Choi DW (1998) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623

86. Schwartz M, Shaked I, Fisher J, Mizrahi T, Schori H (2003) Protective autoimmunity against the enemy within: fighting glutamate toxicity. Trends Neurosci 26:297

87. Takeuchi K, Mizuno T, Zhang G, Wang J, Kawasakuchi J, Kuno R, Suzumura A (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280(10444–10454

88. Zou JY, Crews FT (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 10074:1–24

89. Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, Deacon RA, Rawlins JN, Perry VH (2009) Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry 65:304–312

90. Field R, Campion S, Warren C, Murray C, Cunningham C (2010) Systemic challenge with the TLR3 agonist poly I:C induces amplified IfNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun 24:596–1007
91. Hennessy E, Griffin EW, Cunningham C (2015) Astrocytes are primed by chronic neurodegeneration to produce exaggerated chemokine and cell infiltration responses to acute stimulation with the cytokines IL-1β and TNF-α. J Neurosci 35:8411–8422
92. van Goor WA, van de Beek D, Elkeboom P (2010) Systemic infection and delirium: when cytokines and acetylcholine collide. Lancet 375:773–775
93. Gyoneva S, Davalos D, Biswas D, Swanger SA, Garnier-Amblard E, Loth F, Akassoglou K, Traynelis SF (2014) Systemic inflammation regulates microglial responses to tissue damage in vivo. Glia 62(8):1345–1360
94. Anderson TS, Connors M, Mignagh PN, Coogan AN (2015) Lipopolysaccharide-induced sepsis induces long-lasting affective changes in the mouse. Brain Behav Immun 43:98–109
95. Pekny M, Wilhelmsson U, Pelka M (2014) The dual role of astrocyte activation and reactive giosis. Neurosci Lett 565:30–38
96. O’Callaghan JP, Sirmal K (2005) Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Exp Opin Drug Saf 4:433–442
97. Zhang D, Hu X, Qian L, O’Callaghan JP, Hong JS (2010) Astroglia in CNS pathologies: is there a role for microglia? Mol Neurobiol 41:232–241
98. Kajihara H, Tsutsumi E, Kinoshita A, Nakano J, Takagi K, Takeo S (2001) Activated astrocytes with glycogen accumulation in ischemic penumbra during the early stage of brain infarction: immunohistochemical and electron microscopic studies. Brain Res 909:92–101
99. Goss JR, O'Malley ME, Zou L, Styren SD, Kocheme PM, DeKosky ST (1998) Astrocytes are the major source of nerve growth factor upregulation following traumatic brain injury in the rat. Exp Neurol 149:301–309
100. Choma NE, Santiago-Preuīer L, Erb L, Seye CI, Neary JT, Sun GY, Weissman GA, Gonzalez FA (2004) P2Y receptors activate neuroprotective mechanisms in astrocytic cells. J Neurochem 91:119–132
101. Hansson E, Muyderman H, Leonova J, Alanssen L, Sinclair J, Blomstrand F, Thorin T, Nilsson M, Ronnback L (2000) Astroglia and glutamate in physiology and pathology: aspects on glutamate transport, glutamateinduced cell swelling and gap-junction communication. Neurochem Int 7:317–329
102. Dringen R (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 62:649–671
103. Gegg ME, Beltran B, Salas-Pino S, Bolanos JP, Clark JB, Moncada S, Heales SJ (2003) Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurons: implications for neuroprotection/neurodegeneration? J Neurochem 86:228–237
104. Nakase T, Sohl G, Theis M, Willecke K, Naus CC (2004) Increased apoptosis and inflammation after focal brain ischemia in mice lacking connexin43 in astrocytes. Am J Pathol 164:2067–2075
105. Fields RD, Stevens-Graham B (2002) Neurosciences: new insights into neuron-glia communication. Science 298(5593):556–562
106. Mena MA, García de Yébenes J (2008) Gial cells as players in parkinsonism: the “good”, the “bad”, and the “mysterious” gila. Neuroscientist 14(6):544–560
107. Fuller S, Münch G, Steele M (2009) Activated astrocytes: a therapeutic target in Alzheimer’s disease? Expert Rev Neurother 9(11):1585–1594
108. Janzer RC, Raff MC (1987) Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325:253–257
109. Neuhaus J, Rissau W, Wolburg H (1991) Induction of blood-brain barrier characteristics in bovine brain endothelial cells by rat astroglial cells in transfilter coculture. Ann NY Acad Sci 633:578–580
110. Ronaldson PT, Davis TP (2012) Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr Pharm Des 18:3624–3644
111. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41–53
112. Ballabh P, Braun A, Nedergaard M (2004) The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16(1):1–13
113. Mathiisen TM, Lehe KP, Danbolt NC, Ottersen OP (2010) The perivascular astroglial sheath provides a complete covering of the brain microvessels: an electron microscopic 3D reconstruction. Glia 61(9):1094–1103
114. David S, Kumpers P, van Slyke P, Parikh SM (2013) Mending leaky blood vessels: the angiopoietin-Tie2 pathway in neurodegeneration. Curr Opin Neurobiol 23(5):661–667
115. Zaslavsky E, Nudelman G, Raine CS, John GR (2015) Astrocytic TYMP and VEGFA drive blood-brain barrier opening and exacerbate chemokine and cell infiltration responses to acute stimulation with the cytokines IL-1β and TNF-α. J Neurosci 35:8411–8422
116. Hernandez G, Bruhn A, Ince C (2013) Microcirculation in sepsis: new perspectives. Curr Vasc Pharmacol 11:1369–1377
117. Gimsa U, Mitchison NA, Brunner-Weinzierl MC (2013) Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediators Inflamm 2013:230219
118. Choppoulou C, Tadesse Argaw A, Horng S, Castro K, Zhang J, Asp L, Loo H, Laitman BM, Mariani JN, Straus Farber R, Vieira R, Portela LV (2015) Long-term NMDAR antagonism correlates reduced astrocytic glutamate uptake with anxiety-like phenotype. Front Cell Neurosci 9(219)
